DUBLIN--(BUSINESS WIRE)--The "Drug analysis: Binimetinibi" drug pipelines has been added to ResearchAndMarkets.com's offering.
Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK pathway. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition of the production of various inflammatory cytokines including interleukin-1, -6, and tumor necrosis factor.
The author believes that because half of microsatellite instability-high (MSI-H) tumors also harbor mutations in BRAF, the combination of binimetinib, encorafenib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) , and Erbitux (cetuximab; Eli Lilly/Merck KGaA) has the potential to compete with the programmed death-1 (PD-1) inhibitors currently approved for MSI-H patients. Although this triplet combination could become an important option for colorectal cancer (CRC) patients with BRAF mutations, the author expects that safety, tolerability, and cost considerations will have to be made in order for this pipeline regimen to successfully compete within the market.
Key Topics Covered:
List of Figures
Figure 1: Binimetinib for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary for binimetinib in colorectal cancer
Figure 3: Drug assessment summary for binimetinib in colorectal cancer
Figure 4: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
Figure 5: Binimetinib for melanoma - SWOT analysis
Figure 6: Drug assessment summary of binimetinib in melanoma
Figure 7: Drug assessment summary of binimetinib in melanoma
List of Tables
Table 1: Binimetinib drug profile
Table 2: Binimetinib Phase III data in colorectal cancer
Table 3: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
Table 4: Patients treated with binimetinib in the US and five major EU markets, by country, 2016-25
Table 5: Binimetinib drug profile
Table 6: Binimetinib ongoing Phase III trials in melanoma
Table 7: Binimetinib and encorafenib combination Phase II trial data in melanoma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6l7dmz/binimetinib?w=4
